Our Course

1992:    KBN was founded on October 26, 1992.

1993:    KBN first achieved the mass production of one of its oral antibiotic products, amoxicillin, and put it into the Chinese market.

             Alfacalcidol soft Capsules introduced by TEVA were brought into the market.

             KBN passed the qualification process to become a “National High-tech Enterprises”

1996:    KBN was identified as a technology-intensive and knowledge-intensive enterprise by the state.

             Cefaclor Capsules were put into the market.

1997:    Amoxicillin products were designated to serve as gifts for Prime Minister Li Peng’s visits to six African countries;

             KBN became one of the top 50 Chinese chemical pharmaceutical enterprises in terms of profit

1998:    KBN was the first enterprise in Yunnan and also among the first group nationally to achieve GMP certification
 
1999:    KBN’s amoxicillin products were acclaimed as the “First choice of national users” and as a “Famous brand of Yunnan Province”.

2001:    Then Vice-premier Wu Bangguo visited KBN;

             KBN was granted the certificate of “Famous Chinese enterprise without quality complaints” and the honor of “Best image 

among China’s brand-name enterprises”.

2002:    KBN was selected into the nationally encouraged class of foreign-funded enterprises.

2003:    ARTZ (sodium hyaluronate injection) introduced from SKK of Japan was put onto the market.

2005:    Israel’s TEVA, the world’s biggest generics enterprise, merged with IVAX and thus became a foreign shareholder in KBN.

2006:    KBN was awarded the title of “Excellent enterprise of the non-state economy” by Yunnan Province

             KBN was granted the “Golden Banner for Charitable Donation” jointly issued by the Chinese Red Cross, the government of

Yunnan Province, and the Red.       

             Cross of Yunnan Province.

2007:    KBN was again awarded the “Golden Banner for Charitable Donation” by the government of Yunnan Province and the Red Cross

of Yunnan Province.

2008:    KBN was given the honorary title “Best Enterprise as Selected by the Red Cross” issued by the Chinese Red Cross.

2009:    KBN won the “Social responsibility award of China’s pharmaceutical industry for 2009”.

             Amoxicillin capsules of KBN first entered the “Top Chinese Drug Brands 2009 Ranking List”.

             General Manager Dai Xiaochang of KBN was selected as one of the “Top 10 figures of China’s pharmaceutical enterprises of

2009”;

             General Manager Dai Xiaochang of KBN was written into the large-scale documentary book “We are in China”.

2009:    KBN introduced OC EI8HT from FERNDALE.

2010:    KBN won the title of “Charity enterprise alliance member unit of Yunnan Red Cross”.

             Amoxicillin capsules of KBN entered “2010 Oral Antibiotic Rank List”

             KBN won the general distributorship in Chinese Market for azithromycin (Sumamed) originally researched by Pliva, Croatia.

2011:    KBN was given the “Silver Banner for Charitable Donation” issued by the government of Yunnan Province and Red Cross of

Yunnan Province.

The Amoxicillin capsules of KBN again entered the “Top Chinese Drug Brands 2009 Ranking List”.

2012:    KBN introduced three gynecological products: Promestriene Cream ®, Fem7 ®, and Colposeptine ® from Monaco’s LABORATOIRE

THERAMEX.

2013:    KBN introduced blood-activating rheumatism ointment from Teh Seng Pharmaceutical MFG. Co., Ltd., Taiwan.